# Visugromab in Cachexia International Trial

Source: https://onco.cc/trials/nct07112196/  
OnCo record `nct07112196` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Visugromab, run by CatalYm GmbH, now recruiting.

## Summary

Visugromab in Cachexia International Trial is a phase 2/3 interventional study registered as NCT07112196 by CatalYm GmbH, with 518 participants planned, started 2026-04-16. Conditions listed: Cancer-associated Cachexia. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07112196
- Phase: 2/3
- Setting: Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo in Patients With Cancer-associated Cachexia
- Sponsor: CatalYm GmbH
- Enrolled: 518

## Sources

- ClinicalTrials.gov NCT07112196: https://clinicaltrials.gov/study/NCT07112196

## Connected records

- drugs: [Visugromab](https://onco.cc/drugs/visugromab/)
- companies: [CatalYm](https://onco.cc/companies/catalym/)

---
JSON: https://onco.cc/api/v1/entities/nct07112196.json